<DOC>
	<DOCNO>NCT02462772</DOCNO>
	<brief_summary>The CAPRISA 014 trial aim ass safety acceptability long-acting ( LA ) injectable antiretroviral agent , cabotegravir LA ( GSK1265744 ) , HIV uninfected woman KwaZulu-Natal , South Africa .</brief_summary>
	<brief_title>Safety Acceptability Cabotegravir HIV Uninfected Women KwaZulu-Natal , South Africa</brief_title>
	<detailed_description>The CAPRISA 014 trial design establish safety acceptability cabotegravir LA sexually active , at-risk HIV-uninfected woman . A total 632 HIV uninfected woman ( 18 30 year ) two site KwaZulu-Natal , South Africa enrol . The trial approximately 24 month , additional 12 month post-trial safety observation . The study divide three period : Period 1 - Clinical trial oral lead-in ( 34 day ) - Consenting participant randomize receive daily oral cabotegravir ( 30mg tablet ) daily oral placebo approximately 30 day , assess safety tolerability prior exposure LA injectable formulation . Period 2 - Clinical trial follow-up injectable ( approximately 48-96 week ) - Participants successfully complete Period 1 receive intra-muscular ( IM ) gluteal injection cabotegravir LA ( 800 mg , administer two 400 mg injection ) placebo every 12 week . The end Period 2 mark completion clinical trial follow-up . Period 3 - Post-trial safety follow-up off-product ( approximately 12 month ) - During post-trial safety observation period , participant follow ( product ) approximately 12 month completion period 2 .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Soybean oil , phospholipid emulsion</mesh_term>
	<mesh_term>HIV Integrase Inhibitors</mesh_term>
	<criteria>Able willing provide write informed consent screen , enrol , study . Able willing provide adequate locator information study retention purpose . Sexually active , define vaginal intercourse least past 30 day prior screen . HIV negative testing perform study staff Have negative pregnancy test perform study staff Agree use nonbarrier form contraceptive Agree adhere study visit procedure . Haemoglobin &gt; 11 g/dL , ALT &lt; ULN AST &lt; ULN Total bilirubin &lt; Grade 1 Direct bilirubin &lt; ULN Creatinine clearance â‰¥60 mL/min Hepatitis B surface antigen ( HBsAg ) negative Hepatitis C Ab negative In general good health , assess clinically Past current participation HIV interventional research study concurrent study may interfere study . Clinically significant cardiovascular disease , include : ECG : heart rate &lt; 50 &gt; 100 beat per minute ( one repeat ECG allow screening ; perform day ) QRS duration &gt; 120 msec QTc interval ( B F ) &gt; 450 msec evidence previous myocardial infarction ( pathologic Q wave , ST segment change ( except early repolarization ) conduction abnormality ( include specific leave right complete bundle branch block , Atrioventricular block [ 2nd degree ( type II ) high ] , Wolf Parkinson White syndrome ) sinus pause &gt; 3 second significant arrhythmia , opinion Principal Investigator designee , interfere safety individual participant history nonsustained ( 3 consecutive ventricular ectopic beat ECG screen entry ) sustain ventricular tachycardia History/evidence symptomatic arrhythmia , angina/ischemia , coronary artery bypass graft surgery percutaneous transluminal coronary angioplasty clinically significant cardiac disease Underlying skin disease currently active skin disorder ( e.g. , infection , inflammation , dermatitis , eczema , psoriasis , urticaria ) . Mild case localize disease mild skin condition may exclusionary discretion Principal Investigator designee . Has tattoo dermatological condition overlie buttock region opinion Principal Investigator designee , may interfere interpretation injection site reaction . History acute chronic liver disease ( e.g. , nonalcoholic alcoholic steatohepatitis ) know hepatic biliary abnormality ( exception Gilbert 's syndrome , asymptomatic gallstone , cholecystectomy ) . Coagulopathy ( primary iatrogenic ) would contraindicate IM injection . Active plan use prohibit medication describe SSP manual ( updated regularly Investigator 's Brochure ) . Pregnant currently breastfeed , intend become pregnant and/or breastfeed study . Known Hypersensitivity egg , soya peanut protein . Has condition , base opinion Principal Investigator designee , would preclude provision inform consent , make participation study unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Cabotegravir</keyword>
	<keyword>safety</keyword>
	<keyword>long-acting injectable</keyword>
	<keyword>HIV prevention</keyword>
	<keyword>acceptability</keyword>
</DOC>